GAMMA Investing’s Nektar Therapeutics NKTR Stock Holding History

GAMMA Investing’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$15.6K	Buy	257 +251	+4,183%	+$17.6K	﹤0.01%	3090
2026 Q2	$419	Hold	6	–	–	﹤0.01%	4011
2026 Q1	$432	Buy	+6	New	+$342	﹤0.01%	3971

Other funds holding NKTR

TSC

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GAMMA Investing's NKTR Position: Q3 2026 in Review

GAMMA Investing increased its Nektar Therapeutics (NKTR) stake by 4,183% in Q3 2026, buying an estimated $17.6K and bringing the position to 257 shares worth $15.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3090.

GAMMA Investing first reported a position in NKTR in Q1 2026 and has held it in 3 quarters since. 4 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

GAMMA Investing held 257 shares of Nektar Therapeutics worth $15.6K as of Q3 2026.
GAMMA Investing bought 251 Nektar Therapeutics shares in Q3 2026, an estimated $17.6K.
Nektar Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3090 holding.
GAMMA Investing first reported a position in Nektar Therapeutics in Q1 2026 and has held it in 3 quarters since.
4 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.